How do you use Tysabri in a sentence? See 2 example sentences showing how this word appears in different contexts.
Tysabri in a sentence
Context around Tysabri
- Average sentence length in these examples: 30 words
- Position in the sentence: 0 start, 2 middle, 0 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Tysabri
- In this selection, "tysabri" usually appears in the middle of the sentence. The average example has 30 words, and this corpus slice is mostly made up of statements.
- Around the word, dose and drug stand out and add context to how "tysabri" is used.
- Recognizable usage signals include highest dose tysabri from biosimilars and sclerosis drug tysabri in treating. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "tysabri" sits close to words such as aabb, aabria and aacha, which helps place it inside the broader word index.
Example types with tysabri
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
And do you have any way to protecting the highest dose TYSABRI from biosimilars through the first-generation products. (19 words)
The lion's share of Biogen's stock frustration is related to its pipeline in Alzheimer's disease medications and the failure of its multiple sclerosis drug Tysabri in treating strokes, Leerink analyst Geoffrey Porges said in his note to clients. (41 words)
The lion's share of Biogen's stock frustration is related to its pipeline in Alzheimer's disease medications and the failure of its multiple sclerosis drug Tysabri in treating strokes, Leerink analyst Geoffrey Porges said in his note to clients. (41 words)
And do you have any way to protecting the highest dose TYSABRI from biosimilars through the first-generation products. (19 words)
Example sentences (2)
And do you have any way to protecting the highest dose TYSABRI from biosimilars through the first-generation products.
The lion's share of Biogen's stock frustration is related to its pipeline in Alzheimer's disease medications and the failure of its multiple sclerosis drug Tysabri in treating strokes, Leerink analyst Geoffrey Porges said in his note to clients.